The Trump administration launched the Medicare GLP-1 Bridge program, setting a monthly cost cap of $50 for three weight-loss drugs—Wegovy, the tirzepatide KwikPen version of Zepbound, and orforglipron (Foundayo). The move is designed to expand affordability for older adults, including those with obesity who are more likely to rely on Medicare coverage. The coverage changes also intensify an evidence gap: older adults are underrepresented in early GLP-1 trials, even as the population using these drugs is expected to rise. Clinicians quoted in the report cautioned that “eligibility doesn’t mean benefit automatically,” emphasizing the need to individualize decisions due to frailty, comorbidities, and side-effect risk profiles that vary widely by age and health status.